Sinovac Biotech Ltd. Files 6-K Report
Ticker: SVA · Form: 6-K · Filed: Apr 30, 2024
Sentiment: neutral
Topics: sec-filing, 6-k, compliance
TL;DR
Sinovac Biotech filed a routine 6-K report with the SEC.
AI Summary
Sinovac Biotech Ltd. filed a Form 6-K on April 30, 2024, for the month of April 2024. The filing was signed by Nan Wang, Chief Financial Officer, on April 29, 2024. This report is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates ongoing reporting compliance for Sinovac Biotech Ltd. with the SEC, which is standard for publicly traded foreign private issuers.
Risk Assessment
Risk Level: low — This is a standard, routine filing with no new material information or significant financial changes disclosed.
Key Players & Entities
- Sinovac Biotech Ltd. (company) — Registrant
- Nan Wang (person) — Chief Financial Officer
- April 29, 2024 (date) — Date of signature
- April 30, 2024 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to provide information that the registrant makes or is required to make public in its home country.
Who signed this specific 6-K filing on behalf of Sinovac Biotech Ltd.?
The filing was signed by Nan Wang, Chief Financial Officer, on April 29, 2024.
What is the Commission File Number for Sinovac Biotech Ltd.?
The Commission File Number for Sinovac Biotech Ltd. is 001-32371.
What is the principal executive office address for Sinovac Biotech Ltd.?
The principal executive offices are located at No. 39 Shangdi Xi Rd, Haidian District, Beijing 100085, People's Republic of China.
Does Sinovac Biotech Ltd. file annual reports under Form 20-F or Form 40-F?
Sinovac Biotech Ltd. indicated that it files annual reports under Form 20-F.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-04-29 18:12:36
Filing Documents
- tm2412948d1_6k.htm (6-K) — 9KB
- tm2412948d1_ex99-1.htm (EX-99.1) — 279KB
- 0001104659-24-054243.txt ( ) — 288KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People's Republic of China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SINOVAC BIOTECH LTD. By: /s/ Nan Wang Name: Nan Wang Title: Chief Financial Officer Date: April 29, 2024 Exhibit Index Exhibit 99.1Press Release